EXEL
$41.83
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced r...
Recent News
Exelixis (EXEL) Valuation After Earnings Beat FDA Progress And Cabometyx Label Expansion
Exelixis (EXEL) is back in focus after reporting earnings that beat expectations, supported by higher Cabometyx sales, and after securing FDA acceptance of its zanzalintinib application in metastatic colorectal cancer with a December PDUFA date. See our latest analysis for Exelixis. Despite recent gains after the earnings beat and regulatory updates, the 30 day share price return of a 6.1% decline and the year to date share price return of a 5.4% decline contrast with a stronger 1 year total...
Exelixis Highlights Zanzalintinib RCC Trials, Sequencing Debate, and December CRC PDUFA at Leerink
Exelixis (NASDAQ:EXEL) executives and investors spent part of the discussion at a Leerink event focusing on recent renal cell carcinoma (RCC) data, evolving treatment sequencing debates, and the company’s late-stage pipeline plans around its next-generation tyrosine kinase inhibitor (TKI) zanzalinti
Exelixis Highlights CABOMETYX Growth, Zanzalintinib PDUFA and Pipeline Strategy at Barclays Conference
Exelixis (NASDAQ:EXEL) described its current commercial trajectory, late-stage clinical programs, and strategic priorities during a discussion at a Barclays event featuring Senior Vice President of Strategy and Investor Relations Andrew Peters. Peters emphasized that the company remains anchored by
Exelixis Highlights $2.4B 2026 Outlook, Cabometyx Momentum and Zanzalintinib Catalysts at Conference
Exelixis (NASDAQ:EXEL) detailed its commercial momentum for cabozantinib and outlined key upcoming clinical catalysts for zanzalintinib during a discussion at the Citizens Life Sciences Conference featuring Andrew Peters. Cabozantinib performance and 2026 outlook Peters said 2025 was “an exciting y
Exelixis (EXEL) Down 2.8% Since Last Earnings Report: Can It Rebound?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.